26
JUN
2014
Dr. Mike Tranfaglia with son, Andy

Fragile X Clinical Trial: Novartis trial results are in, and they’re not pretty

AFQ056 Fragile X Clinical Trial showed Negative Results This year’s Gordon Conference just finished, and Novartis presented their results for the first time (though...
23
MAY
2014
USA Today logo

FRAXA Featured in USA Today: Disappointments aside, optimism for Fragile X drugs

On May 22, 2014, USA Today featured an article surrounding FRAXA’s optimism for continuing to seek effective treatments for Fragile X, despite negative results in...
28
APR
2014
Mike Tranfaglia, MD, FRAXA Chief Scientific Officer

FRAXA Science Update Teleconference: Latest news about Fragile X Clinical Trials

When 10:30 am Eastern Daylight Time on Wednesday April 30, 2014   Topics FRAXA Medical Director, Dr. Michael Tranfaglia will discuss the latest results from the Novartis...
24
APR
2014

Novartis Discontinues Development of mavoglurant (AFQ056) for Fragile X Syndrome

Novartis Clinical Trials in Fragile X Ended Novartis has announced that the company will be discontinuing its development program in Fragile X for its lead mGluR5 antagonist,...
01
APR
2014

Experimental Drug FRAX486 Reverses Schizophrenia In Mice

A new study shows that one of a class of compounds known as PAK inhibitors, appears to have reversed behaviors associated with schizophrenia and restored some lost brain cell...
26
MAR
2014

New clue to Fragile X and autism found inside brain cells

Researchers led by Dr. Karen O’Malley at Washington University School of Medicine in St. Louis have published results of their work on mGluR5 and Fragile X syndrome....
25
MAR
2014

What Treatments Work for FXTAS?

Many older family members in the fragile X community are affected by FXTAS (Fragile X-associated Tremor/Ataxia Syndrome). We all hope that knowing the underlying cause of...
11
MAR
2014

Postdoctoral and Graduate Students welcome at Gordon Research Seminar on Fragile X and Autism

The role of the early-career researcher in today’s biological sciences cannot be overstated. Every seminal finding, advance and path-breaking work has as its lead author a...
share this Email this to someoneShare on FacebookShare on LinkedInTweet about this on TwitterShare on Google+Pin on PinterestShare on StumbleUpon